Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
BackgroundSimilarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
The neu oncogene encodes an epidermal growth factor receptor-related protein
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Nature · doi:10.1038/319226a0 · Cited by 1,117
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091
Post‐translational modifications and activation of p53 by genotoxic stresses
Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,079
Regulation of p53 in response to DNA damage
Lakin, N. D., & Jackson, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203015 · Cited by 987 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundShieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Interaction of the p53-Regulated Protein Gadd45 with Proliferating Cell Nuclear Antigen
Smith, M. L., Chen, I.-T., Zhan, Q., Bae, I., Chen, C.-Y., Gilmer, T. M., Kastan, M. B., O'Connor, P. M., & Fornace, A. J. (1994) · Science · doi:10.1126/science.7973727 · Cited by 944
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Cisplatin : current status and new developments
Prestayko, A. W., Crooke, S. T., Carter, S. K., & Laboratories, B. (1980) · Cited by 747
How nucleotide excision repair protects against cancer
Friedberg, E. C. (2001) · Nature Reviews Cancer · doi:10.1038/35094000 · Cited by 730
Requirement for ERK Activation in Cisplatin-induced Apoptosis
Wang, X., Martindale, J. L., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004583200 · Cited by 675
Strasser, A. (1994) · Cell · doi:10.1016/0092-8674(94)90201-1 · Cited by 666
Mechanisms of p53-dependent apoptosis
Schuler, M., & Green, D. R. (2001) · Biochemical Society Transactions · doi:10.1042/bst0290684 · Cited by 641
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature Reviews Cancer · doi:10.1038/35094077 · Cited by 568
Premature p34 cdc2 Activation Required for Apoptosis
Shi, L., Nishioka, W. K., Th'ng, J., Bradbury, E. M., Litchfield, D. W., & Greenberg, A. H. (1994) · Science · doi:10.1126/science.8108732 · Cited by 557
Mechanisms of DNA Excision Repair
Sancar, A. (1994) · Science · doi:10.1126/science.7801120 · Cited by 555
Eastman, A. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 539
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.
Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., & Cho, K. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.3988 · Cited by 526
MEKK1/JNK signaling stabilizes and activates p53
Fuchs, S. Y., Adler, V., Pincus, M. R., & Ronai, Z. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10541 · Cited by 524
Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
Leppä, S., & Bohmann, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203173 · Cited by 522 · cited 1×
“These transcription factors, therefore, may act as both inhibitors and facilitators of apoptosis depending on the cell type and context (Leppa and Bohmann, 1999).”
BackgroundCross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis
Gottlieb, T. M., Leal, J. F. M., Seger, R., Taya, Y., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205181 · Cited by 472
Anticancer drug targets: cell cycle and checkpoint control
Shapiro, G. I., & Harper, J. W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci9054 · Cited by 464
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., & Reed, E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117388 · Cited by 446
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA
Pinto, A. L., & Lippard, S. J. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(85)90001-0 · Cited by 437
ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53
Tang, D., Wu, D., Hirao, A., Lahti, J. M., Liu, L., Mazza, B., Kidd, V. J., Mak, T. W., & Ingram, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111598200 · Cited by 422
Duckett, D. R., Drummond, J. T., Murchie, A. I., Reardon, J. T., Sancar, A., Lilley, D. M., & Modrich, P. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6443 · Cited by 421
The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 410
Sequence-specific transcriptional activation is essential for growth suppression by p53.
Pietenpol, J. A., Tokino, T., Thiagalingam, S., el-Deiry, W. S., Kinzler, K. W., & Vogelstein, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.1998 · Cited by 406
Cisplatin (cis-diamminedichloroplatinum II)
Prestayko, A. W., D'Aoust, J. C., Issell, B. F., & Crooke, S. T. (1979) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(79)80057-2 · Cited by 405
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Mechanisms of transcription-coupled DNA repair
Svejstrup, J. Q. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm703 · Cited by 380
Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy
(1991) · Springer eBooks · doi:10.1007/978-1-4899-0738-7 · Cited by 374
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J., & Sancar, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10394 · Cited by 347
High-Dose Cisplatin in Hypertonic Saline
OZOLS, R. F., CORDEN, B. J., JACOB, J., WESLEY, M. N., OSTCHEGA, Y., & YOUNG, R. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-1-19 · Cited by 333
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
SOUSSI, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332
High mobility group protein-1 (HMG-1) is a unique activator of p53
Jayaraman, L., Moorthy, N. C., Murthy, K. G. K., Manley, J. L., Bustin, M., & Prives, C. (1998) · Genes & Development · doi:10.1101/gad.12.4.462 · Cited by 321
Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II)
Eastman, A., & Schulte, N. (1988) · Biochemistry · doi:10.1021/bi00413a022 · Cited by 312
Köberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300
Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60095-0 · Cited by 300
Drummond, J. T., Anthoney, A., Brown, R., & Modrich, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295
Bellon, S. F., Coleman, J. H., & Lippard, S. J. (1991) · Biochemistry · doi:10.1021/bi00246a021 · Cited by 291
Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin
Persons, D. L., Yazlovitskaya, E. M., & Pelling, J. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004267200 · Cited by 290
Sensitization of Cancer Cells Treated With Cytotoxic Drugs to Fas-Mediated Cytotoxicity
Micheau, O., Solary, E., Hammann, A., Martin, F., & Dimanche-Boitrel, M.-T. (1997) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/89.11.783 · Cited by 281
Preclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
Chaney, S. G., & Sancar, A. (1996) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 280
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275
Eischen, C. M., Kottke, T. J., Martins, L. M., Basi, G. S., Tung, J. S., Earnshaw, W. C., Leibson, P. J., & Kaufmann, S. H. (1997) · Blood · doi:10.1182/blood.v90.3.935 · Cited by 269
Mistry, P., Kelland, L., Abel, G., Sidhar, S., & Harrap, K. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.279 · Cited by 261
Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C., & Scher, H. I. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1384 · Cited by 254
New members of the Bcl-2 family and their protein partners
Farrow, S. N., & Brown, R. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90009-x · Cited by 247
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, D. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243
Whole grain food intake and cancer risk
Chatenoud, L., Tavani, A., La Vecchia, C., Jacobs, D. R., Negri, E., Levi, F., & Franceschi, S. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980703)77:1<24::aid-ijc5>3.0.co;2-1 · Cited by 238
New platinum antitumor complexes
Kelland, L. R. (1993) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(93)90042-3 · Cited by 237
Mechanisms of switching on p53: a role for covalent modification?
Meek, D. W. (1999) · Oncogene · doi:10.1038/sj.onc.1202951 · Cited by 236
p53-Mdm2--the affair that never ends
Alarcon-Vargas, D. (2002) · Carcinogenesis · doi:10.1093/carcin/23.4.541 · Cited by 233
lzquierdo, M. A., Zee, A. G. J. V. D., Vermorken, J. B., Valk, P. V. D., Belien, J. A. M., Giaccone, G., Scheffer, G. L., Flens, M. J., Pinedo, H. M., Kenemans, P., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.16.1230 · Cited by 220
p38 MAPK signalling cascades: ancient roles and new functions
Martín-Blanco, E. (2000) · BioEssays · doi:10.1002/1521-1878(200007)22:7<637::aid-bies6>3.0.co;2-e · Cited by 213
He, Q., Liang, C. H., & Lippard, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100108697 · Cited by 209
Kelland, L. R., Sharp, S. Y., O’Neill, C. F., Raynaud, F. I., Beale, P. J., & Judson, I. R. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00141-5 · Cited by 206
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
Mello, J. A., Acharya, S., Fishel, R., & Essigmann, J. M. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90149-0 · Cited by 199
Cabelguenne, A., Blons, H., de Waziers, I., Carnot, F., Houllier, A.-M., Soussi, T., Brasnu, D., Beaune, P., Laccourreye, O., & Laurent-Puig, P. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1465 · Cited by 191
Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis
Slater, A. F. G., Nobel, C. S. I., Maellaro, E., Bustamante, J., Kimland, M., & Orrenius, S. (1995) · Biochemical Journal · doi:10.1042/bj3060771 · Cited by 188
Goto, S., Iida, T., Cho, S., Oka, M., Kohno, S., & Kondo, T. (1999) · Free Radical Research · doi:10.1080/10715769900301121 · Cited by 187
Metallothionein gene expression and resistance to cisplatin in human ovarian cancer
Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J., Ozols, R. F., Fojo, A. T., & Hamilton, T. C. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450306 · Cited by 185
van der Zee, A. G., Hollema, H., Suurmeijer, A. J., Krans, M., Sluiter, W. J., Willemse, P. H., Aalders, J. G., & de Vries, E. G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.70 · Cited by 184
Hills, C., Kelland, L., Abel, G., Siracky, J., Wilson, A., & Harrap, K. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.108 · Cited by 183
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
Andrews, P., Murphy, M., & Howell, S. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00254568 · Cited by 176
p16 INK4A Participates in a G 1 Arrest Checkpoint in Response to DNA Damage
Shapiro, G. I., Edwards, C. D., Ewen, M. E., & Rollins, B. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.378 · Cited by 165
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
Houldsworth, J., Xiao, H., Murty, V., Chen, W., Ray, B., Reuter, V. E., Bosl, G. J., & Chaganti, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201770 · Cited by 161
Enhanced DNA repair and resistance to cisplatin in human ovarian cancer
Lai, G., Ozols, R. F., Smyth, J. F., Young, R. C., & Hamilton, T. C. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90325-5 · Cited by 156
Yeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Ea, C.-K., & Cheng, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00908-5 · Cited by 155
Makin, G., Corfe, B. M., Griffiths, G. J., Thistlethwaite, A., Hickman, J. A., & Dive, C. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6306 · Cited by 151
Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
Fan, S., Chang, J. K., Smith, M. L., Duba, D. E., Fornace, A. J., & O'Connor, P. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201052 · Cited by 150
Nakayama, K., Kanzaki, A., Ogawa, K., Miyazaki, K., Neamati, N., & Takebayashi, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10608 · Cited by 146
The role of interleukin-13 in infectious diseases and allergy
Brombacher, F. (2000) · BioEssays · doi:10.1002/1521-1878(200007)22:7<646::aid-bies7>3.0.co;2-9 · Cited by 137
Wolf, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R., & Smyth, J. F. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390607 · Cited by 135
Donahue, B. A., Augot, M., Bellon, S. F., Treiber, D. K., TONEY, J. H., Lippard, S. J., & Essigmann, J. M. (1990) · Biochemistry · doi:10.1021/bi00476a032 · Cited by 132
Platinum, Gold, and Other Metal Chemotherapeutic Agents
Lippard, S. J. (1983) · ACS symposium series · doi:10.1021/bk-1983-0209 · Cited by 129
Cisplatin resistance and oncogenes - a review
Dempke, W. C. M., Voigt, W., Grothey, A. A., Hill, B. T., & Schmoll, H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200004000-00001 · Cited by 126
Cisplatin/carboplatin cross-resistance in ovarian cancer
Gore, M., Fryatt, I., Wiltshaw, E., Dawson, T., Robinson, B., & Calvert, A. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.356 · Cited by 116
Woessmann, W., Chen, X., & Borkhardt, A. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0502-y · Cited by 113
Regulation of p73 by c-Abl through the p38 MAP kinase pathway
Sánchez‐Prieto, R., Lobo, V. J. S.-A., Servitja, J., & Gutkind, J. S. (2002) · Oncogene · doi:10.1038/sj.onc.1205134 · Cited by 113
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
Beale, P. J., Rogers, P., Boxall, F. E., Sharp, S. Y., & Kèlland, L. R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0939 · Cited by 112
Qin, L. F., & Ng, I. O. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00720-0 · Cited by 111
Regulation of p53: Intricate Loops and Delicate Balances
OREN, M., DAMALAS, A., GOTTLIEB, T., MICHAEL, D., TAPLICK, J., LEAL, J. F. M., MAYA, R., MOAS, M., SEGER, R., TAYA, Y., et al. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04669.x · Cited by 110
Sheibani, N., Jennerwein, M. M., & Eastman, A. R. (1989) · Biochemistry · doi:10.1021/bi00433a055 · Cited by 107
Heiger-Bernays, W. J., Essigmann, J. M., & Lippard, S. J. (1990) · Biochemistry · doi:10.1021/bi00488a037 · Cited by 105
Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes
Jennerwein, M. M., Eastman, A. R., & Khokhar, A. (1989) · Chemico-Biological Interactions · doi:10.1016/0009-2797(89)90061-6 · Cited by 104
MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA
Zdraveski, Z. Z., Mello, J. A., Farinelli, C. K., Essigmann, J. M., & Marinus, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105382200 · Cited by 103
Glutathione-mediated activation of anticancer platinum(IV) complexes
Eastman, A. R. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90581-8 · Cited by 101
Lee, K. B., Parker, R. J., Bohr, V., Cornelison, T., & Reed, E. (1993) · Carcinogenesis · doi:10.1093/carcin/14.10.2177 · Cited by 101
Shen, D.-W., Goldenberg, S., Pastan, I., & Gottesman, M. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<108::aid-jcp13>3.0.co;2-4 · Cited by 96
Activation of MEK Kinase 1 by the c-Abl Protein Tyrosine Kinase in Response to DNA Damage
Kharbanda, S., Pandey, P., Yamauchi, T., Kumar, S., Kaneki, M., Kumar, V., Bharti, A., Yuan, Z.-M., Ghanem, L., Rana, A., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.4979-4989.2000 · Cited by 93
Kèlland, L. R., Barnard, F. J., Evans, I. G., Murrer, B. A., Theobald, B. R. C., Wyer, S. B., Goddard, P. M., Jones, M., & Valenti, M. R. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00016a004 · Cited by 92
Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation
Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., Dincalci, M., & Broggini, M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900122 · Cited by 92
Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V. S., Rosbe, K. W., Brann, T. W., Korbut, T. T., & Frei, E. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470214 · Cited by 91
Tsai, C.-M., Yu, D., Chang, K.-T., Wu, L.-H., Perng, R.-P., Ibrahim, N. K., & Hung, M.-C. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.9.682 · Cited by 90
Requirement of ATM in UVA-induced Signaling and Apoptosis
Zhang, Y., Ma, W.-Y., Kaji, A., Bode, A. M., & Dong, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110245200 · Cited by 87
El-Khateeb, M., Appleton, T. G., Gahan, L. R., Charles, B. G., Berners‐Price, S. J., & Bolton, A.-M. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00146-4 · Cited by 84
Ormerod, M. G., O’Neill, C., Robertson, D. M., Kèlland, L. R., & Harrap, K. R. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050413 · Cited by 84
Identification of p53 genetic suppressor elements which confer resistance to cisplatin
Gallagher, W. M., Cairney, M., Schott, B., Roninson, I. B., & Brown, R. H. (1997) · Oncogene · doi:10.1038/sj.onc.1200813 · Cited by 83
Smith, M. L., Kontny, H. U., Bortnick, R., & Fornace, A. J. (1997) · Experimental Cell Research · doi:10.1006/excr.1996.3402 · Cited by 79
Hagopian, G. S., Mills, G. B., Khokhar, A. R., Bast, R. C., & Siddik, Z. H. (1999) · PubMed · Cited by 78
Self-citationSpecificin VitroBinding of p53 to the Promoter Region of the Human Mismatch Repair Gene hMSH2
Scherer, S. J., Welter, C., Zang, K. D., & Dooley, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0663 · Cited by 76
Cui, W., Yazlovitskaya, E. M., Mayo, M. S., Pelling, J. C., & Persons, D. L. (2000) · Molecular Carcinogenesis · doi:10.1002/1098-2744(200012)29:4<219::aid-mc1004>3.0.co;2-d · Cited by 76
Ikeguchi, M., Liu, J., & Kaibara, N. (2002) · APOPTOSIS · doi:10.1023/a:1013556727182 · Cited by 74
Li, J., Delmastro, D. A., Vaisman, A., Solle, M., & Chaney, S. G. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050568 · Cited by 74
Specificity of platinum–DNA adduct repair
Chaney, S. G., & Vaisman, A. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00149-x · Cited by 69
Ovarian cancer: new clinical approaches
Ozols, R. F. (1991) · Cancer Treatment Reviews · doi:10.1016/0305-7372(91)90027-w · Cited by 67
The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis
Mandic, A., Viktorsson, K., Heiden, T., Hansson, J., & Shoshan, M. C. (2001) · Melanoma Research · doi:10.1097/00008390-200102000-00002 · Cited by 67
Faivre, S. J., Kalla, S., Cvitkovic, E., Bourdon, O., Hauteville, D., Dourte, L. M., Bensmaïne, M. A., Itzhaki, M., Marty, M. E., & Extra, J.-M. (1999) · Annals of Oncology · doi:10.1023/a:1008334215414 · Cited by 65
DNA damage checkpoints: Implications for cancer therapy
O'Connor, P. M., & Fan, S. (1996) · Springer eBooks · doi:10.1007/978-1-4615-5873-6_16 · Cited by 62
Mechanisms of Resistance to Platinum Drugs
Eastman, A. R., Schulte, N. A., Sheibani, N., & Sorenson, C. M. (1988) · Springer eBooks · doi:10.1007/978-1-4613-1717-3_20 · Cited by 62
Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage
Larminat, F., & Bohr, V. A. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3005 · Cited by 59
Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells
Bello, B. D., Valentini, M., Zunino, F., Comporti, M., & Maellaro, E. (2001) · Oncogene · doi:10.1038/sj.onc.1204618 · Cited by 56
Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., & Howell, S. B. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.6.1222 · Cited by 52
Enhanced resistance of HeLa cells to cisplatin by overexpression of γ-glutamyltransferase
Daubeuf, S., Leroy, P., Paolicchi, A., Alfonso Pompella, C., Wellman, M., Galteau, M. M., & Visvikis, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01118-8 · Cited by 49
Metallothionein levels in ovarian tumours before and after chemotherapy
Murphy, D., McGown, A. T., Crowther, D., Mander, A., & Fox, B. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.160 · Cited by 44
DNA as a Target for Anticancer Coordination Compounds
Roberts, J. J., & Pera, M. (1983) · ACS symposium series · doi:10.1021/bk-1983-0209.ch001 · Cited by 43
Marx, D., Meden, H., Ziemek, T., Lenthe, T., Kühn, W., & Schauer, A. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10169-1 · Cited by 38
Pan, B., Yao, K.-S., Monia, B. P., Dean, N. M., McKay, R. A., Hamilton, T. C., & O'Dwyer, P. J. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00841-9 · Cited by 37
Kolfschoten, G. M., Pinedo, H. M., Scheffer, P. G., Schlüper, H. M. M., Erkelens, C. A. M., & Boven, E. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5689 · Cited by 36
Miyake, H., Hara, I., Yamanaka, K., Arakawa, S., & Kamidono, S. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68155-4 · Cited by 34
Deng, X., Kim, M., Vandier, D., Jung, Y.-J., Rikiyama, T., Sgagias, M. K., Goldsmith, M. E., & Cowan, K. H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00948-8 · Cited by 34
Cocker, H. A., Hobbs, S., Tiffin, N., Pritchard‐Jones, K., Pinkerton, R., & Kèlland, L. R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2145 · Cited by 30
Siddik, Z. H., Hagopian, G. S., Thai, G., Tomisaki, S., Toyomasu, T., & Khokhar, A. R. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00144-0 · Cited by 28
Self-citationJennerwein, M. M., Eastman, A. R., & Khokhar, A. R. (1991) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(91)90044-p · Cited by 27
Chemotherapy for Advanced Epithelial Ovarian Cancer
Ozols, R. F. (1992) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30316-2 · Cited by 27
Modulation of cytotoxicity of chemotherapeutic drugs by activated H-γas
Fan, J., Banerjee, D., Stambrook, P. J., & Bertino, J. R. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00101-9 · Cited by 26
ras mutation and platinum resistance in human ovarian carcinomas in vitro
Holford, J., Rogers, P., & Kèlland, L. R. (1998) · International Journal of Cancer · Cited by 25
D’Incalci, M., Bonfanti, M., Pifferi, A., Mascellani, E., Tagliabue, G., Berger, D. P., & Fiebig, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00191-9 · Cited by 22
Loss of p73 Induction in a Cisplatin-Resistant Bladder Cancer Cell Line
Ono, Y., Nonomura, N., Harada, Y., Fukui, T., Tokizane, T., Sato, E., Nakayama, M., Nishimura, K., Takahara, S., & Okuyama, A. (2001) · Molecular Urology · doi:10.1089/109153601750124267 · Cited by 20
Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance
Ségal-Bendirdjian, E., Mannone, L., & Jacquemin‐Sablon, A. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400357 · Cited by 20
REPAIR OF cis-PLATINUM (II) DIAMMINE DICHLORIDE-INDUCED DNA DAMAGE AND CELL SENSITIVITY
Roberts, J. J., & Fraval, H. N. A. (1980) · Elsevier eBooks · doi:10.1016/b978-0-12-565050-2.50009-7 · Cited by 20
New Therapies for Ovarian Cancer
Schilder, R. J., & Ozols, R. F. (1992) · Cancer Investigation · doi:10.3109/07357909209032755 · Cited by 19
High Dose Cisplatin and Drug Resistance: Clinical and Laboratory Correlations
Ozols, R. F., Hamilton, T. C., Reed, E., Poirier, M. C., Masuda, H., Lai, G., & Young, R. C. (1988) · Springer eBooks · doi:10.1007/978-1-4613-1717-3_21 · Cited by 12
Genomic Dissection Reveals Locus Response to Stress for Mammalian Acetylcholinesterase
Grant, A. D., Shapira, M., & Soreq, H. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1015112407079 · Cited by 7
Zuev, Y. S. (2002) · International Polymer Science and Technology · doi:10.1177/0307174x0202900615 · Cited by 5
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
“The cytotoxic effect is likely a result of inhibition of replication by cisplatin-DNA adducts and induction of apoptosis (Siddik, 2003).”
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Iida, N., Dzutsev, A., Stewart, C. A., Smith, L., Bouladoux, N., Weingarten, R. A., Molina, D. A., Salcedo, R., Back, T., Cramer, S., et al. (2013) · Science · doi:10.1126/science.1240527 · Cited by 2,251
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.